OBJECTIVE: To evaluate the efficacy of "compliance therapy" for improving adherence to prescribed drug treatment among patients with schizophrenia. DESIGN: Randomised controlled trial. SETTING:Urban catchment area psychiatric service. PARTICIPANTS: 94 consecutive admissions of patients with schizophrenia, 56 agreed to participate. INTERVENTION: Compliance therapy and non-specific counselling, each consisting of 5 sessions lasting 30-60 minutes. MAIN OUTCOME MEASURES: Compliance with drug treatment at one year; attitudes to treatment, symptomatology, insight, and quality of life at one year; length of "survival" in the community, bed days, and rehospitalisation rates at two years. RESULTS:Compliance therapy did not confer a major advantage over non-specific therapy in improving compliance at one year (43% (12/28) v 54% (15/28), difference -11% (95% confidence interval -37% to 15%) or in any of the secondary outcome measures-symptomatology, attitudes to treatment, insight, global assessment of functioning, and quality of life. CONCLUSION:Compliance therapy may not be of benefit to patients with schizophrenia. Attitudes to treatment at baseline predicted adherence one year later and may be a clinically useful tool.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of "compliance therapy" for improving adherence to prescribed drug treatment among patients with schizophrenia. DESIGN: Randomised controlled trial. SETTING: Urban catchment area psychiatric service. PARTICIPANTS: 94 consecutive admissions of patients with schizophrenia, 56 agreed to participate. INTERVENTION: Compliance therapy and non-specific counselling, each consisting of 5 sessions lasting 30-60 minutes. MAIN OUTCOME MEASURES: Compliance with drug treatment at one year; attitudes to treatment, symptomatology, insight, and quality of life at one year; length of "survival" in the community, bed days, and rehospitalisation rates at two years. RESULTS: Compliance therapy did not confer a major advantage over non-specific therapy in improving compliance at one year (43% (12/28) v 54% (15/28), difference -11% (95% confidence interval -37% to 15%) or in any of the secondary outcome measures-symptomatology, attitudes to treatment, insight, global assessment of functioning, and quality of life. CONCLUSION: Compliance therapy may not be of benefit to patients with schizophrenia. Attitudes to treatment at baseline predicted adherence one year later and may be a clinically useful tool.
Authors: E Diaz; H B Levine; M C Sullivan; M J Sernyak; K A Hawkins; J A Cramer; S W Woods Journal: J Psychiatry Neurosci Date: 2001-09 Impact factor: 6.186
Authors: Peter F Buckley; Donna A Wirshing; Prameet Bhushan; Joseph M Pierre; Seth A Resnick; William C Wirshing Journal: CNS Drugs Date: 2007 Impact factor: 5.749
Authors: Stefan Priebe; Julia Sinclair; Alexandra Burton; Stamatina Marougka; John Larsen; Mike Firn; Richard Ashcroft Journal: J Med Ethics Date: 2010-06-27 Impact factor: 2.903
Authors: Tatiana L Taylor; Helen Killaspy; Christine Wright; Penny Turton; Sarah White; Thomas W Kallert; Mirjam Schuster; Jorge A Cervilla; Paulette Brangier; Jiri Raboch; Lucie Kalisová; Georgi Onchev; Hristo Dimitrov; Roberto Mezzina; Kinou Wolf; Durk Wiersma; Ellen Visser; Andrzej Kiejna; Patryk Piotrowski; Dimitri Ploumpidis; Fragiskos Gonidakis; José Caldas-de-Almeida; Graça Cardoso; Michael B King Journal: BMC Psychiatry Date: 2009-09-07 Impact factor: 3.630